Rogerio C. Lilenbaum, MD

Rogerio C. Lilenbaum, MD, discusses the clinical implications of the FDA approval of lurbinectedin in metastatic small cell lung cancer.

Rogerio C. Lilenbaum, MD, discusses the challenges of integrating telehealth services in lung cancer.

Rogerio C. Lilenbaum, MD, discusses the promising future direction of immunotherapy in patients with advanced lung cancer.

Rogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer. 

Rogerio C. Lilenbaum, MD, discusses using PD-L1 as a predictive biomarker for immunotherapy and the search for additional biomarkers in lung cancer.